TGTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TG Therapeutics Inc (TGTX) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the company has shown impressive financial growth in the latest quarter and has positive revenue projections, the technical indicators are bearish, and there is no strong trading signal from Intellectia Proprietary Trading Signals. Additionally, the options data and analyst ratings are mixed, and the stock's short-term trend suggests a potential decline in the next day. Given the investor's profile and the current data, holding off on purchasing this stock is recommended for now.
The technical indicators for TGTX are bearish. The MACD is below 0 and negatively expanding, the RSI is neutral at 37.125, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below its pivot level of 28.98, with key support at 27.939 and resistance at 30.021. Overall, the technical outlook suggests a downward bias in the short term.
TG Therapeutics projects global revenue of $825 million to $850 million in 2026, driven by its multiple sclerosis treatment Briumvi.
The company launched a new platform, NextInMS.com, to support MS patients, and partnered with Christina Applegate for a national awareness campaign.
Financial performance in Q3 2025 shows significant growth, with revenue up 92.79% YoY and net income up 9974.61% YoY.
Technical indicators are bearish, suggesting potential short-term price declines.
Analyst ratings are mixed, with one firm lowering its price target and another maintaining an underperform rating despite raising the target.
Stock trend analysis indicates a 90% chance of a -2.2% decline in the next day and only a modest 1.39% gain in the next week.
In Q3 2025, TG Therapeutics reported revenue of $161.71 million, up 92.79% YoY. Net income increased to $390.89 million, a massive 9974.61% YoY growth. EPS rose to 2.43, up 12050.00% YoY. However, gross margin dropped to 82.63%, down 7.01% YoY. Overall, the financial performance is strong, with significant growth in revenue and profitability.
Analyst ratings are mixed. JPMorgan maintains an Overweight rating but lowered the price target from $49 to $46. BofA raised its price target from $13 to $15 but maintains an Underperform rating, citing concerns about the sustainability of the biotech sector's recent positive momentum.
